Want to see TSE:SONA full AI Analyst Report?
SONA Stock Chart & Stats
C$0.40
>-C$0.01(-2.00%)
At close: 4:00 PM EST
C$0.40
>-C$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeC$0.26 - C$0.91
Previous CloseN/A
Volume36.80K
Average Volume (3M)124.26K
Market Cap
C$32.03M
Enterprise ValueC$32.88M
Total Cash (Recent Filing)C$36.55K
Total Debt (Recent Filing)C$318.31K
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding114,375,250
10 Day Avg. Volume87,178
30 Day Avg. Volume124,263
Financial Highlights & Ratios
PEG Ratio-2.89
Price to Book (P/B)-1.80K
Price to Sales (P/S)0.00
P/FCF Ratio-35.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Gold Nanorod TechnologyOwning proprietary gold nanorod materials gives SONA a technical differentiation that can form an IP-based moat. If commercialization succeeds, this specialized material can be licensed or sold as a recurring consumable to diagnostics and life-science customers, enabling durable revenue streams and partnership leverage.
Strategic Focus On Diagnostics & Research MarketsBeing positioned in diagnostics and life-science ties SONA to markets that demand validated reagents and labeling agents. These are structural B2B markets with recurring needs for quality materials, meaning successful product qualification could translate into steady, long-term commercial demand and customer stickiness.
Modest Absolute Debt BurdenLow nominal debt limits fixed financing obligations and reduces near-term insolvency pressure compared with highly leveraged peers. This modest debt position gives management more flexibility in financing strategy (equity or grants) while pursuing commercialization and reduces immediate cash interest burdens.
Bears Say
Zero Revenue / No Commercial ScaleThe company reports no revenue across multiple years and TTM, indicating it is pre-commercial. Without demonstrated sales or product-market fit, the business relies on external funding and faces significant execution risk to build sustainable revenue, making long-term viability uncertain.
Persistent Cash Burn And Negative Free Cash FlowFCF consistently mirrors net losses, translating accounting losses into real cash burn. This structural negative cash generation creates ongoing financing needs, increases dilution or credit risk, and pressures management to secure capital before commercialization milestones are reached.
Negative Shareholders' Equity And Shrinking AssetsThe shift to negative equity and falling total assets materially weakens the balance sheet, reducing borrowing capacity and creditor confidence. This structural deterioration raises solvency concerns and limits strategic options, increasing the risk that future financing terms will be costly or dilutive.
Sona Nanotech Inc News
SONA FAQ
What was Sona Nanotech Inc’s price range in the past 12 months?
Sona Nanotech Inc lowest stock price was C$0.26 and its highest was C$0.91 in the past 12 months.
What is Sona Nanotech Inc’s market cap?
Sona Nanotech Inc’s market cap is C$32.03M.
When is Sona Nanotech Inc’s upcoming earnings report date?
Sona Nanotech Inc’s upcoming earnings report date is Sep 24, 2026 which is in 79 days.
How were Sona Nanotech Inc’s earnings last quarter?
Sona Nanotech Inc released its earnings results on Jun 29, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.
Is Sona Nanotech Inc overvalued?
According to Wall Street analysts Sona Nanotech Inc’s price is currently Overvalued.
Does Sona Nanotech Inc pay dividends?
Sona Nanotech Inc does not currently pay dividends.
What is Sona Nanotech Inc’s EPS estimate?
Sona Nanotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sona Nanotech Inc have?
Sona Nanotech Inc has 114,375,250 shares outstanding.
What happened to Sona Nanotech Inc’s price movement after its last earnings report?
Sona Nanotech Inc reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sona Nanotech Inc?
Currently, no hedge funds are holding shares in TSE:SONA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sona Nanotech Inc
Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic test designed to detect the SARS-CoV-2 spike protein antigen in saliva from individuals suspected of having the virus. The company also offers Gemini and Omni gold nanorods, with the latter specifically engineered for medical uses, in addition to providing contract services. These versatile products are utilized in a wide array of applications, such as targeted drug delivery, environmental and food safety monitoring, cellular visualization, cancer therapy, liposuction treatments, and diagnostic tools for medical, consumer, military, and veterinary sectors.
Technical Analysis
BioMark Diagnostics
―
Eastwood Bio-Medical Canada
―
StageZero Life Sciences Ltd
―
Medmira
―
ZYUS Life Sciences
―
Options Prices
Currently, No data available
---